Overview

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
The main purpose of this two-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Esperas Pharma Inc.
Treatments:
Gemcitabine